ProCE Banner Activity

Optimal Treatment for Patients With Progressive RCC After 1 or More Previous Lines of Therapy

Slideset Download
Download these slides from a live webinar for the most recent data on the selection and sequencing of therapy for patients with advanced RCC after progression on first-line therapy.

Released: June 05, 2022

Expiration: June 04, 2023

No longer available for credit.

Share

Faculty

Katy Beckermann

Katy Beckermann, MD, PhD

Assistant Professor
Department of Internal Medicine
Division of Hematology/Oncology
Vanderbilt University
Nashville, Tennessee

Provided by

Provided by National Comprehensive Cancer Network.
ProCE Banner

Supporters

Supported by educational grants from

AVEO Pharmaceuticals, Inc.

Eisai Inc.

Exelixis

Merck Sharp & Dohme Corp.

Pfizer, Inc.

Faculty Disclosure

Primary Author

Katy Beckermann, MD, PhD

Assistant Professor
Department of Internal Medicine
Division of Hematology/Oncology
Vanderbilt University
Nashville, Tennessee

Katy E. Beckermann, MD, PhD, has disclosed that she has received consulting fees from Aravive, AVEO, Bristol Myers Squibb, Exelixis, and Seagen and funds for research from Bristol Myers Squibb.